BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25866742)

  • 1. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.
    Doty RA; Liu J; McFadden G; Roy EJ; MacNeill AL
    Oncolytic Virother; 2013 Jan; 2():1-17. PubMed ID: 25866742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.
    Kinn VG; Hilgenberg VA; MacNeill AL
    Oncolytic Virother; 2016; 5():59-71. PubMed ID: 27579297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
    Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
    Viruses; 2020 May; 12(5):. PubMed ID: 32397134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma.
    Woo JK; Kim TG; Im NY; Son KY; Cho M; Jeong YJ; Hong JI; Kang B; Enkhtaivan G; Cho NH; Alain T; Park DG; Lee YS
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
    Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
    PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
    Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
    J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.
    Jazowiecka-Rakus J; Sochanik A; Rusin A; Hadryś A; Fidyk W; Villa N; Rahman MM; Chmielik E; Franco LS; McFadden G
    Mol Ther Oncolytics; 2020 Sep; 18():335-350. PubMed ID: 32775618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
    Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
    Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
    Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
    Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.
    Nounamo B; Liem J; Cannon M; Liu J
    Mol Ther Oncolytics; 2017 Sep; 6():90-99. PubMed ID: 28875159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
    Pisklakova A; McKenzie B; Zemp F; Lun X; Kenchappa RS; Etame AB; Rahman MM; Reilly K; Pilon-Thomas S; McFadden G; Kurz E; Forsyth PA
    Neuro Oncol; 2016 Aug; 18(8):1088-1098. PubMed ID: 26962017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
    Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.
    Irwin CR; Favis NA; Agopsowicz KC; Hitt MM; Evans DH
    PLoS One; 2013; 8(12):e84134. PubMed ID: 24391902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting gallbladder carcinoma: bone marrow-derived stem cells as therapeutic delivery vehicles of myxoma virus.
    Weng M; Zhang M; Qin Y; Gong W; Tang Z; Quan Z; Wu K
    Chin Med J (Engl); 2014; 127(12):2350-6. PubMed ID: 24931255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
    Lilly CL; Villa NY; Lemos de Matos A; Ali HM; Dhillon JS; Hofland T; Rahman MM; Chan W; Bogen B; Cogle C; McFadden G
    Mol Ther Oncolytics; 2017 Mar; 4():31-40. PubMed ID: 28345022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus.
    Dryja P; Curtsinger HD; Bartee MY; Bartee E
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme.
    Burton C; Das A; McDonald D; Vandergrift WA; Patel SJ; Cachia D; Bartee E
    Oncolytic Virother; 2018; 7():107-116. PubMed ID: 30538967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
    McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
    Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
    Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
    Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.